Skip to main content
Galapagos NV logo

Galapagos NV — Investor Relations & Filings

Ticker · GLPG ISIN · BE0003818359 LEI · 549300QKJ78IY0IOV655 BR Manufacturing
Open in API
Filings indexed 2,865 across all filing types
Latest filing 2017-11-06 Investor Presentation
Country BE Belgium
Listing BR GLPG

About Galapagos NV

https://www.glpg.com/

Galapagos NV is a biotechnology company focused on transforming patient outcomes through scientific innovation. The company is strategically concentrating its efforts on its cell therapy platform, which is engineered for the scalable, decentralized, and rapid production of next-generation treatments. A key feature of this platform is a median 7-day vein-to-vein delivery time. In parallel with this focus, Galapagos is actively seeking partners to take over its portfolio of small molecule assets, including its TYK2 inhibitor program for autoimmune indications. This strategic shift allows the company to prioritize the growth and development of its cell therapy pipeline through internal discovery, partnerships, and acquisitions.

Recent filings

Filing Released Lang Actions
Consistent safety findings and durable activity with filgotinib treatment of rheumatoid arthritis patients up to week 84 in DARWIN 3 study
Investor Presentation Classification · 95% confidence The document is a press release dated November 5, 2017, announcing that Galapagos NV is presenting data from its filgotinib studies (DARWIN 3) and GLPG1972 at the American College of Rheumatology Annual Meeting 2017. It details the content of the presentations (long-term safety, efficacy data, etc.) and provides contact information. This is not a full regulatory report (like 10-K or IR), nor is it a transcript (CT) or a formal earnings release (ER). It is an announcement about scientific data being presented at a medical conference, which often falls under Investor Presentation (IP) if it contains detailed strategic/scientific slides, or sometimes Regulatory Filing (RNS) if it's a general announcement. Given the detailed overview of scientific abstracts and the context of presenting clinical trial data to investors/the medical community, 'Investor Presentation' (IP) is the most fitting category, as these announcements often precede or accompany the actual presentation materials shared with investors. However, since the text itself is an announcement *about* presentations rather than the presentation slides themselves, and it is a general corporate update, it could also be classified as a Regulatory Filing (RNS) if IP is reserved strictly for the slide deck. Comparing the options, 'Investor Presentation' (IP) is used for detailed presentations focusing on financials/strategy. This document details scientific findings and study abstracts, which are core components of investor/medical presentations. I will classify it as IP as it is a detailed communication of clinical trial results intended for investors and the medical community, even if it's the announcement wrapper.
2017-11-06 English
6-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Galapagos NV, pursuant to SEC rules. It includes a press release as Exhibit 99.1 dated November 5, 2017. The document is relatively short (2590 characters) and primarily serves to submit a press release and incorporate it by reference into other registration statements. There is no substantive financial data or detailed report content here, only an announcement and attachment of a press release. According to the rules, such filings that are short and serve to provide or announce other documents without containing the full report itself should be classified as Regulatory Filings (RNS).
2017-11-06 English
Galapagos moving forward in CF programs at NACFC 2017
Regulatory Filings Classification · 95% confidence The document is a press release from Galapagos NV dated November 2, 2017, detailing the progress of their Cystic Fibrosis (CF) program to be presented at the North American Cystic Fibrosis Conference (NACFC 2017). It lists specific presentation and poster titles, speaker names, and times. This format—announcing participation in a scientific/industry conference with details of presentations—is characteristic of an Investor Presentation (IP) or a general corporate update. Since it is a formal announcement detailing scientific and clinical progress intended for investors and the public, and it is not a full financial report (10-K, IR), an earnings release (ER), or a transcript (CT), the most fitting category is Investor Presentation (IP), as it serves to present company progress and pipeline updates to the investment community.
2017-11-02 English
Galapagos moving forward in CF programs at NACFC 2017
Report Publication Announcement Classification · 99% confidence The document is a press release dated November 2, 2017, detailing scientific presentations (posters and oral sessions) that the company, Galapagos, will present at the North American Cystic Fibrosis Conference (NACFC 2017). It lists abstracts, speakers, and provides general company information and forward-looking statements. This type of announcement, which details scientific progress, clinical trial updates, and upcoming presentations at industry conferences, is characteristic of an Investor Presentation (IP) or a general scientific/R&D update, rather than a formal regulatory filing like a 10-K, ER, or IR. Since it is a detailed update focused on R&D progress and future data presentation, Investor Presentation (IP) is the most fitting category, as these often accompany or precede investor briefings about pipeline progress.
2017-11-02 English
6-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed with the SEC by a foreign private issuer, Galapagos NV. Form 6-K is used by foreign private issuers to report material information that is required to be made public in their home country or filed with a foreign stock exchange. The document includes a press release as Exhibit 99.1 and references incorporation by reference into registration statements. The document length is short (2590 characters) and primarily serves as a regulatory filing to disclose a press release rather than containing detailed financial data or a full report. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and not as a full report like an Annual Report or Interim Report.
2017-11-02 English
PR Q3 2017_ENG.pdf
Earnings Release Classification · 100% confidence The document is an initial announcement of quarterly financial results (Q3 2017) for Galapagos NV. It provides key financial highlights, management commentary, and a summary table of consolidated figures. Crucially, it explicitly states that the full Q3 2017 report is available separately on the company's website, which classifies this document as an Earnings Release (ER) rather than the full report itself. 9M 2017
2017-11-02 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.